According to IMARC Group, the global migraine drugs market size reached USD 4.60 Billion in 2025 and is projected to reach USD 6.50 Billion by 2034, expanding at a CAGR of 3.90% during 2026–2034. This sustained migraine drugs market growth reflects the rising global prevalence of migraine disorders, the rapid clinical adoption of calcitonin gene-related peptide (CGRP)-targeted therapies,...